ASLAN Release: Dr Carl Firth Appointed To Singapore’s Health And Biomedical Sciences International Advisory Council

Published: Jul 07, 2017

Singapore, 7 July 2017 – ASLAN Pharmaceuticals (ASLAN, 6497.TT), a biotech company focused on the development of immunotherapies and targeted agents for Asia prevalent tumour types, today announced that its Chief Executive Officer, Dr Carl Firth, has been appointed to serve on the Health and Biomedical Sciences International Advisory Council (IAC) of Singapore.

The IAC is a high-level Council that steers the development of Singapore’s biomedical sector. Advising the Agency for Science, Technology and Research (A*STAR) and the Ministry of Health, the Council comprises of distinguished medical professionals and eminent scientists from the global biomedical sciences community who share their expertise and insight on industry trends.

Commenting on his appointment, Dr Carl Firth, Chief Executive Officer of ASLAN Pharmaceuticals said: “ASLAN’s success has been made possible because of the country’s strong biotech ecosystem. I am honoured to join the esteemed Council to contribute to the advancement of Singapore as a global biotech hub.”

The Council is chaired by eminent biochemist Sir Richard Sykes, Chairman of the Imperial College Healthcare NHS Trust. Other members of the Council include Sir Leszek Borysiewicz, Vice Chancellor of the University of Cambridge; Dame Sally Davies, Chief Medical Officer for England; and Professor Victor J Dzau, President of the National Academy of Medicine.

For more information on the Council, please visit:


Media contacts
Chris Fang
ASLAN Pharmaceuticals
Tel: +886 2 2758 3333

Emma Thompson / Stephanie Tan
Spurwing Communications
Tel: +65 6340 7287

About ASLAN Pharmaceuticals

ASLAN Pharmaceuticals (6497.TT) is an oncology focused biotechnology company developing a portfolio of immunotherapies and targeted drugs, focusing on Asia prevalent tumour types. Led by a highly experienced management team with global pharmaceutical expertise, ASLAN is headquartered in Singapore with a platform that reaches across the region via its offices in Taiwan, China and Australia. The Company is developing 5 drugs addressing multiple indications including biliary tract cancer, gastric cancer and colorectal cancer, and has two global pivotal studies in biliary tract cancer and gastric cancer underway. ASLAN’s partners include Array BioPharma, Bristol-Myers Squibb, Almirall and CSL.

Back to news